Nanotechnology for Pediatric Retinoblastoma Therapy

Nanotechnology for Pediatric Retinoblastoma Therapy

Retinoblastoma is a rare, sometimes hereditary, pediatric cancer. In high-income countries this disease has a survival rate approaching 100%, while in low- and middle-income countries the prognosis is fatal for about 80% of cases. Depending on the stage of the disease, different therapeutic protocol...

Full description

Bibliographic Details
Main Authors: Eleonora Russo, Andrea Spallarossa, Bruno Tasso, Carla Villa, Chiara Brullo
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Pharmaceuticals
Subjects:
retinoblastoma
conventional chemotherapy
cancer
pediatric rare disease
nanoparticle
nanomedicine
Online Access:https://www.mdpi.com/1424-8247/15/9/1087

Internet

https://www.mdpi.com/1424-8247/15/9/1087

Similar Items